Education
About Us
Working with TipRanks
Follow Us
BioLife Solutions (BLFS)
NASDAQ:BLFS
BLFS Stock Chart & Stats
$20.17
-$0.09(-0.33%)
At close: 4:00 PM EST
$20.17
-$0.09(-0.33%)
Day’s Range― - ―
52-Week Range$19.10 - $29.62
Previous CloseN/A
Volume44.73K
Average Volume (3M)363.00K
Market Cap
$974.21M
Enterprise Value$982.16M
Total Cash (Recent Filing)$120.18M
Total Debt (Recent Filing)$11.02M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
May 07, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,300,000
10 Day Avg. Volume392,925
30 Day Avg. Volume363,004
Financial Highlights & Ratios
PEG Ratio2.20
Price to Book (P/B)3.10
Price to Sales (P/S)12.00
P/FCF Ratio57.40
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue10.21
Enterprise Value/Gross Profit15.81
Enterprise Value/Ebitda-122.46
Forecast
1Y Price Target
$33.20Price Target Upside64.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.1
Revenue Forecast (FY)$111.06M
Bulls Say, Bears Say
Bulls Say
Guidance And MarginsForward guidance that exceeds expectations combined with management plans to expand adjusted EBITDA margins through operating leverage points to improving profitability and potential upside to earnings power.
R&D Center And Product InnovationThe opening of the Aby J. Mathew Center for Biopreservation Excellence is expected to accelerate development of next‑generation cryopreservation products and showcase the full cell processing portfolio to support future product wins.
Strategic Refocus Via DivestitureProceeds from the sale of the evo cold chain business enable a sharper strategic focus on higher‑margin cell processing and biopreservation activities, improving resource allocation for core growth areas.
Bears Say
Growth And Customer Acquisition RiskLower‑than‑projected adoption of products or difficulty in securing additional customers could slow revenue growth and hinder the company's ability to scale commercial operations.
Revenue Base SensitivityA smaller revenue base increases sensitivity to timing shifts in orders, which raises the risk of short‑term earnings volatility and larger reported swings from isolated events.
BioLife Solutions News
BLFS FAQ
What was BioLife Solutions’s price range in the past 12 months?
BioLife Solutions lowest stock price was $19.10 and its highest was $29.62 in the past 12 months.
What is BioLife Solutions’s market cap?
BioLife Solutions’s market cap is $974.21M.
When is BioLife Solutions’s upcoming earnings report date?
BioLife Solutions’s upcoming earnings report date is May 07, 2026 which is in 63 days.
How were BioLife Solutions’s earnings last quarter?
BioLife Solutions released its earnings results on Feb 26, 2026. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.012 by $0.052.
Is BioLife Solutions overvalued?
According to Wall Street analysts BioLife Solutions’s price is currently Undervalued.
Does BioLife Solutions pay dividends?
BioLife Solutions does not currently pay dividends.
What is BioLife Solutions’s EPS estimate?
BioLife Solutions’s EPS estimate is 0.01.
How many shares outstanding does BioLife Solutions have?
BioLife Solutions has 48,300,000 shares outstanding.
What happened to BioLife Solutions’s price movement after its last earnings report?
BioLife Solutions reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.012. Following the earnings report the stock price went up 7.651%.
Which hedge fund is a major shareholder of BioLife Solutions?
Currently, no hedge funds are holding shares in BLFS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLife Solutions Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.20 (64.60% Upside)
$33.20 (64.60% Upside)
Blogger Sentiment
Bullish
BLFS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 60.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $838.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.00%
12-Months-Change
Fundamentals
Return on Equity
-5.20%
Trailing 12-Months
Asset Growth
2.73%
Trailing 12-Months
Company Description
BioLife Solutions
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. It markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was incorporated in 1987 and is headquartered in Bothell, Washington.
BLFS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong top-line growth (29% YoY), significant improvement in adjusted EBITDA and a return to profitability, strengthened liquidity after divesting a product line, and clear 2026 guidance signaling continued growth and expected GAAP profitability. Notable challenges include a decline in gross margin driven by product mix and bag-yield issues (a 2–3 point gross margin headwind in H2 2025), customer/product concentration, a one-time tax true-up that boosted margins, and longer adoption cycles for strategic cross-sell and partnership initiatives. On balance, operational execution, cash position, market leadership in BPM, and improved profitability outweigh the headwinds, though the margin and concentration risks merit monitoring.View all BLFS earnings summariesBLFS Revenue Breakdown
45.91% Cell processing
36.05% Freezer and thaw
18.04% Biostorage services
BLFS Stock 12 Month Forecast
Average Price Target
$33.20
▲(64.60% Upside)
Technical Analysis
Azenta
―
Staar Surgical
―
Pulse Biosciences
―
Sanara MedTech
―
Kestra Medical Technologies Ltd.
―
Ownership Overview
Currently, No data available
---